Skip to main content

Table 3 Association between era (2013 versus 2006) and administration of intravenous magnesium

From: Increases in intravenous magnesium use among hospitalized patients: an institution cross-sectional experience

Model Odds Ratio [95 % CI] P
Unadjusted 5.07 [3.00-8.58] <0.001
Model 1a 5.09 [3.00-8.62] <0.001
Model 1b 5.60 [3.25-9.66] <0.001
Model 1c 5.60 [3.24-9.67] <0.001
Model 1d 5.98 [3.33-10.74] <0.001
Model 1e 9.24 [4.78-17.87] <0.001
Model 1f 12.89 [6.23-26.68] <0.001
Model 1g 13.91 [6.21-31.17] <0.001
  1. Adjusted for:
  2. aage, gender
  3. bfactors in a) and comorbidities (ischemic heart disease, diabetes, atrial fibrillation, cancer, heart failure, chronic kidney disease)
  4. cfactors in b) and medications (diuretics, proton pump inhibitors)
  5. dfactors in c) and low admission magnesium
  6. efactors in d) and admission ward location (cardiology, coronary care unit, medicine ward, surgical ward mixed medicine/surgery ward)
  7. ffactors in e) and cardiac indication for intravenous magnesium
  8. gfactors in e) and cardiac or other indication for intravenous magnesium